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ABSTRACT 
 
In October of 1985, the Department of Health and Human Services’ (DHHS’) Secretary’s 
Task Force on Black and Minority Health released a report documenting inequities in the health 
status of African Americans and other minority groups.  Since the report’s release, numerous 
federal agencies have implemented programming to address the issue, and Congress has passed 
legislation in efforts to eliminate the inequities.  The Food and Drug Administration, however, 
has remained largely silent on the issue.  This paper identifies and defines racial and ethnic 
disparities in health status, discusses the history of government responses to health disparities, 
and applies the new Office of Minority Health Strategic Framework as a guide for defining the 
role the FDA can and should play in the effort to eliminate racial and ethnic health disparities.  
 
   3 
I. WHAT ARE HEALTH DISPARITIES? 
Health disparities have been defined as “those differences in health status among 
population groups which are avoidable and which are unfair or seen as unfair.”
1  More precise 
definitions can vary, depending on the disease, and can be measured by differences in incidence, 
mortality, or survival rates, among other indicators.
2  This paper mainly addresses racial and 
ethnic disparities in health status, as opposed to disparities in health care.  Health status 
indicators refer to incidences of mortality (death) or morbidity (illness); whereas health care 
indicators typically measure differences in treatment approaches.  These racial and ethnic 
differences in health status “often result from the effects of life long, intergenerational social 
exclusion (e.g., racism and socioeconomic disadvantage).”
3  Despite efforts to reduce or 
eliminate the inequalities through social policies and changes to the health care system, the 
differences have persisted
4 and “likely represent a nexus between historic socioeconomic 
disadvantage, racism and residential segregation.”
5  
In October of 1985, the Department of Health and Human Services’ (DHHS’) Secretary’s 
Task Force on Black and Minority Health released a report documenting inequities in the health 
status of African Americans and other minority groups.
6  The Task Force was commissioned the 
                                                 
1 Institute for Alternative Futures, The DRA Project, Most Important Disparity Reducing Advances in US 
Healthcare &Public Health 4 (2006). 
2 Id. 
3 Kevin Fiscella, Eliminating Disparities in Healthcare Through Quality Improvement, in ELIMINATING 
HEALTHCARE DISPARITIES IN AMERICA: BEYOND THE IOM REPORT 141, 142 (Richard Allen Williams 
ed., 2007). 
4 Randall W. Maxey and Richard Allen Williams, Second-Class Medicine: Implications of Evidence-
Based Medicine for Improving Minority Access to the Correct Pharmaceutical Therapy, in ELIMINATING 
HEALTHCARE DISPARITIES IN AMERICA: BEYOND THE IOM REPORT 99, 100 (Richard Allen Williams 
ed., 2007) (“Health inequality represents one of the most persistent, ubiquitous, and troubling phenomena 
in the United States health system.”). 
5 Fiscella, supra note 3, at 143. 
6 Centers for Disease Control and Prevention, Perspectives in Disease Prevention and Health Promotion 
Report of the Secretary's Task Force on Black and Minority Health, 35(8) Morbidity and Mortality   4 
prior year “in response to the national paradox of steady improvement in overall health, with 
substantial inequities in the health of U.S. minorities.”
7  The report was the result of a 
comprehensive review of morbidity and mortality data regarding Black, Hispanic, Asian/Pacific 
Islander, and Native American populations in relation to whites.  It was the first study of its kind 
to explore the persistent racial inequalities in health outcomes on such a comprehensive scale.
8  
The study consisted of a review of mortality data for over forty disease categories to determine 
areas where minority populations experience “excess deaths” – defined as “the difference 
between the number of deaths observed in the minority populations and the number that would 
have been expected if the minority population had the same age- and sex-specific death rates as 
the nonminority population.”
9  For specific causes of death that were deemed priority areas, the 
Task Force formed subcommittees which then conducted additional research on the “etiology; 
associated physiologic, cultural, and societal factors; means for improving treatment; and 
possible intervention strategies to prevent excess deaths in minority groups.”
10  The 
subcommittees also considered non-medical determinants of health, including demographic 
information and health education.
11  Researchers found that eighty percent of the excess 
mortality of these minority groups could be attributed to six causes of death: Cancer, 
Cardiovascular Disease and Stroke, Chemical Dependency, Diabetes, Homicides and 
Unintentional Injuries, and Infant Mortality.
12  In light of these findings, the report outlined 
                                                                                                                                                            
Weekly Report 109 (1986), http://www.cdc.gov/mmwr/preview/mmwrhtml/00000688.htm (last visited 
May 15, 2008). 
7 Id. 
8 See Garth Graham, Quality of Care and Health Disparities: The Evolving Role of the Government, in 
ELIMINATING HEALTHCARE DISPARITIES IN AMERICA: BEYOND THE IOM REPORT 197, 201 (Richard 
Allen Williams ed., 2007) (Providing general overview of the 1985 Task Force Report). 
9 Centers for Disease Control and Prevention, supra note 6. 
10 Id. 
11 Id. 
12 Id. The findings of the 1985 Task Force with respect to these six causes are summarized below:   5 
several recommendations and specific actions that DHHS should take to eliminate these 
disparities in health.
13 
Over twenty years after the release of the Task Force report, health disparities have 
persisted.  According to statistics from the Centers for Disease Control and Prevention, “African 
Americans are more likely than any other racial and ethnic group to develop cancer, and 30 
percent more likely than whites to die from it. Hispanics living in the United States are 50 
                                                                                                                                                            
Cancer. Cancer accounts for 16% of excess mortality among black males under age 70 years and 10% for 
black females. Cardiovascular disease and stroke. Cardiovascular diseases account for 24% of excess 
mortality among black males and 41% among black females. Chemical dependency, measured by deaths 
due to cirrhosis. Cirrhosis of the liver, which is associated with excessive use of alcohol, accounts for 
13% of excess mortality among Native American males and 22% among Native American females under 
age 70 years. Diabetes. Diabetes accounts for 38% of excess deaths among Mexican-born Hispanic 
females. Homicides and accidents (unintentional injuries). Homicides account for 60% of excess 
mortality among Hispanics under 65 years of age. Unintentional injuries account for 44% of excess deaths 
among male, and 30% among female, Native Americans. Homicides and unintentional injuries account 
for 19% of excess mortality among black males under age 70 years and 38% for those under age 45 years. 
For black females, the disparities are somewhat less--6% and 14%, respectively. A substantial proportion 
of excess deaths due to homicide and unintentional injury may be associated with excessive use of alcohol 
and other drugs. Infant mortality. Of excess deaths among black females up to age 45 years, death in the 
first year of life accounts for 35% of that excess. The relative ratio of average age-adjusted, sex-specific 
mortality in minority populations, compared to that in the nonminority population, by selected cause, 
suggests the relative importance of specific health problems within each group. Id. 
13 Id. 
The Task Force made eight main recommendations to the Secretary, each of which was followed by 
several specific suggestions:  
1. Implement an outreach campaign, specifically designed for minority populations, to disseminate 
targeted health information, educational materials, and program strategies.  
2. Increase patient education by developing materials and programs responsive to minority needs and by 
improving provider awareness of minority cultural and language needs.  
3. Improve the access, delivery, and financing of health services to minority populations through 
increased efficiency and acceptability. 
4. Develop strategies to improve the availability and accessibility of health professionals to minority 
communities through communication and coordination with nonfederal entities. 
5. Promote and improve communication and coordination among federal agencies in administering 
existing programs for improving the health status and availability of health professionals to minorities. 
6. Provide technical assistance and encourage efforts by local and community agencies to meet minority-
health needs. 
7. Improve the quality, availability, and use of health data pertaining to minority populations. 
8. Adopt and support research to investigate factors affecting minority health, including risk-factor 
identification, education interventions, and prevention and treatment services.  Id.   6 
percent more likely than whites to suffer from diabetes, and the incidence of diabetes among 
Native Americans is more than twice that for whites.”
14 
The persistent trend of racial and ethnic minority groups experiencing higher morbidity 
and mortality rates is a public health concern because much of the disparity is observed for 
preventable diseases and conditions.
15  Research has shown that socioeconomic conditions in 
minority communities such as “less access to healthy foods; fewer opportunities for physical 
activity; and constant advertising of alcohol, cigarettes, and junk food” play a role in increasing 
the risk for these diseases.
16  Many of the corresponding risk factors can be mitigated through 
increased government regulation with attention to public health concerns; however, such policy 
efforts cannot ignore the impact that America’s history of segregation and prejudice has had on 
both the health care sector and on other social factors that can impact health.  The health status 
and health care inequities observed by race are often rationalized as variations by socioeconomic 
status or health insurance; however there is evidence that race “in many instances has an 
independent effect on health; that is, the effects of race cannot be fully accounted for by the other 
indicators of rank.”
17  America bears the burden of its long history of the enslavement, 
internment, and segregation of various minority groups, and the impact of this relationship on the 
health of certain populations cannot be ignored.  More than just reflecting differences in health 
status, health disparities represent a social injustice in American society, which “leads to a wide 
range of adverse health consequences, as reflected by disparities in health status and access to 
                                                 
14 Edward M. Kennedy, The Role of the Federal Government In Eliminating Health Disparities, 24 
Health Affairs 452, 452. 
15 Id. at 456. 
16 Id. 
17 David Mechanic, Disadvantage, Inequality, And Social Policy, 21 Health Affairs 48, 48 (2002).   7 
health services within or between populations.”
18  As with any social injustice, it is the 
responsibility of the relevant government authorities to legislate, regulate, and take all necessary 
measures to right the wrongs.
19 
Since the causes of disparities in health status lie well beyond simply differences in 
health care, adequately addressing health disparities requires adopting a holistic and 
comprehensive view of health.  The World Health Organization (WHO) has defined health as “a 
state of complete physical, mental and social well-being and not merely the absence of disease or 
infirmity.”
20  The Organization has developed a Commission on Social Determinants of Health 
that “examines a similarly broad range of social factors, including water, sanitation, and food 
production.”
21  The persistence of inequalities in health status over the past few decades of 
measurement has shown that answering the question of why some people are healthier than 
others requires a similarly broad examination of the societal contributors to health and the ways 
in which the government can intervene to protect disadvantaged populations in the interest of 
public health. 
 
 
 
 
 
                                                 
18 Barry S. Levy and Victor W. Sidel, The Nature of Social Injustice and Its Impact on Public Health, in 
SOCIAL INJUSTICE AND PUBLIC HEALTH 5, 7 (Barry S. Levy and Victor W. Sidel eds., 2006). 
19 Id. at 13. 
20 Preamble to the Constitution of the World Health Organization as adopted by the International Health 
Conference, New York, 19-22 June, 1946; signed on 22 July 1946 by the representatives of 61 States 
(Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 
1948., http://www.who.int/about/definition/en/print.html (last visited May 16, 2008). 
21 Institute for Alternative Futures, The DRA Project, supra note 1 at 12.   8 
II. THE GOVERNMENT RESPONSE 
 
AGENCY ACTION 
In the immediate wake of the 1985 Task Force report, the U.S. Department of Health and 
Human Services (DHHS) created an Office of Minority Health (OMH) to take the lead in 
research and programmatic efforts to eliminate disparities.  OMH is charged with “improv[ing] 
and protect[ing] the health of racial and ethnic minority populations through the development of 
health policies and programs that will eliminate health disparities.”
22  In the early 1990s, the 
Clinton administration implemented several programs to address health disparities, including the 
Healthy People 2010 initiative, Health Disparity Collaboratives, Racial and Ethnic Approaches 
to Community Health (REACH), and Excellence Centers to Eliminate Ethnic/Racial Disparities 
(EXCEED).
23  Several agencies within DHHS also took the initiative to implement targeted 
programs of their own.  In 1998, the Health Resources and Services Administration (HRSA) 
identified six priority areas for reducing health disparities:  Infant Mortality, Cancer Screening 
and Management, Cardiovascular Disease, Diabetes, HIV/AIDS, and Immunizations.
24  
The release of another report, this time issued by the Institute of Medicine (IOM), created 
a flurry of government activity over health disparities again in 2002.  The report, Unequal 
Treatment: Confronting Racial and Ethnic Disparities in Health Care, showed that these 
inequities had persisted since 1985, and it outlined the areas in which African Americans and 
other minority groups were receiving lower quality health care or were experiencing poorer 
                                                 
22 The Office of Minority Health, About OMH, 
http://www.omhrc.gov/templates/browse.aspx?lvl=1&lvlID=7 (last visited May 16, 2008). 
23 Kennedy, supra note 14 at 453. 
24 Institute for Alternative Futures, The DRA Project, supra note 1 at 7-8.   9 
health outcomes.
25  After the report’s release, the term “health disparity” entered the common 
vernacular within the government and became an urgent policy matter.  In addition to the 
formation of the Office of Minority Health within the Department of Health and Human 
Services, nearly every state established their own Office of Minority Health.
26  Furthermore, 
several of the major agencies within DHHS have either created an office of minority health to 
address relevant concerns or have dedicated a section on their websites to minority issues.
27  
However, developing a federal agency-level response to combat health disparities presents a 
challenge because “[t]he federal government and the public in general have never defined an 
overarching strategy for investing in the health of the nation.”
28 
While congressional awareness of and attention to the problem of health disparities is 
growing, a persistent focus on solely medical interventions as a solution
29 overlooks the many 
social factors at play.  Many of the public policies advocated through government efforts have 
focused on direct access to medical services as the primary approach to reducing disparities, and 
some of the literature on health disparities argues that “[t]he most important immediate action in 
response to social injustice against racial and ethnic minorities that leads to disparate health 
                                                 
25 Smedley, Brian D., Adrienne Y. Stith, and Alan R. Nelson, Eds., Committee on Understanding and 
Eliminating Racial and Ethnic Disparities in Health Care, Unequal Treatment: Confronting Racial and 
Ethnic Disparities in Health Care (National Academies Press, 2003), http://www.iom.edu/?id=16740.  
26 See Office of Minority Health Resource Center, State Offices of Minority and Multicultural Health 
Liaison Map, http://www.omhrc.gov/images/stateliaisons.htm (last visited May 16, 2008). 
27 See generally, Administration on Aging, http://www.aoa.gov/prof/adddiv/adddiv.asp; AHRQ, 
http://www.ahrq.gov/research/minorix.htm; Centers for Disease Control and Prevention, Office of 
Minority Health and Health Disparities, http://www.cdc.gov/omhd/Default.htm; Health Resources and 
Services Administration, http://www.ask.hrsa.gov/Minority.cfm; National Institutes of Health, National 
Center on Minority Health and Health Disparities, http://www.ncmhd.nih.gov/. 
28 Nicole Lurie, What The Federal Government Can Do About The Nonmedical Determinants of Health, 
21 Health Affairs 94, 102 (2002). 
29 Kennedy, supra note 14 at 453. Senator Kennedy asserts, “Most members of Congress would agree that 
the progress is far from adequate. Fortunately, more and more members on both sides of the aisle are 
increasingly concerned by the severity of the minority health crisis and understand the need to address it 
more effectively, through a federal action plan that increases minorities’ access to health care and 
improves the quality of care they receive.”   10 
outcomes is the equitable provision of health care.”
30  However, this approach ignores the 
importance of social and environmental factors.  
Not all aspects of the government response have even accepted the existence of 
disparities outright, however.  A 2003 Institute of Medicine report was censored before its 
release to “strike the term disparity from a congressionally mandated annual report on – 
‘healthcare disparities.’”
31  HHS leaders also ordered the researchers to “delete their conclusion 
that racial disparities are ‘pervasive in our healthcare system’ and to remove findings of disparity 
in care for cancer, cardiac disease, AIDS, asthma, and other illnesses.”
32  While the full report 
was later released after news of the censorship leaked, the controversy highlighted the fact that 
efforts to develop strategies to address the problem may face the additional obstacle of 
convincing officials with the power for change that a race-specific problem worth addressing 
exists at all. 
 
A LEGISLATIVE HISTORY 
In 2007, the Minority Health and Health Disparity Elimination Act was introduced into 
the Senate.
33  If enacted, the bill “would authorize nearly $500 million to improve health care for 
racial and ethnic minority and other health disparity populations.”
34  Additionally, the proposed 
                                                 
30 Carol Easley Allen and Cheryl E. Easley, Racial and Ethnic Minorities, in Social Injustice and Public 
Health 46, 63 (Barry S. Levy and Victor W. Sidel eds., 2006).  
31 M. Gregg Bloche, Healthcare and the Politics of Race, in ELIMINATING HEALTHCARE DISPARITIES IN 
AMERICA: BEYOND THE IOM REPORT 67, 68 (Richard Allen Williams ed., 2007) (internal citations 
omitted). 
32 Id. 
33 Minority Health Improvement and Health Disparity Elimination Act, H.R.3333/S.1576, 110
th Cong. 
(1st Sess. 2007). 
34 Barack Obama – U.S. Senator for Illinois, Obama Introduces Bill to Eliminate Health Care Disparities, 
June 7, 2007, http://obama.senate.gov/press/070607-obama_introduce_13/ (last visited May 16, 2008); 
see Minority Health Improvement and Health Disparity Elimination Act, H.R.3333/S.1576, 110
th Cong. 
(1st Sess. 2007).   11 
legislation “reauthorizes and strengthens the Office of Minority Health, mandates uniform data 
collection standards for federal health programs and creates an advisory committee at the FDA to 
address genomic issues related to racial and ethnic minorities.”
35  This bill is just the latest in the 
effort to address the persistence in health disparities through legislation. 
In 2000, Congress passed the Minority Health and Health Disparities Research and 
Education Act.  The Act mandated that several agencies take direct action to research and collect 
data on health disparities and created the National Center for Minority Health and Health 
Disparities at the National Institutes of Health (NIH).
36  Additionally, the new law required the 
Agency for Healthcare Research and Quality (AHRQ) to research minority health and health 
disparities and called for the National Academy of Sciences to review the minority data 
collection practices of the Department of Health and Human Services (DHHS).
37  In 2004, the 
National Academy of Sciences released the results of its review in a report titled Eliminating 
Health Disparities: Data and Measurement Needs, outlining current federal data collection 
practices.
38  AHRQ fulfilled its mandate by releasing “annual reports on health care quality and 
health care disparities, which has allowed better monitoring and evaluation of trends in the care 
of minority and other underserved populations.”
39  Congress also addressed health disparities 
through a provision in the 2000 appropriations bill requiring the Institute of Medicine to research 
the potential causes of racial and ethnic health disparities.  The resulting report, Unequal 
Treatment (referenced above) “is considered the premier study on racial and ethnic disparities 
and provides actionable recommendations for the medical, public health, and research 
                                                 
35 Id. 
36 Kennedy, supra note 14 at 453.  
37 Id. 
38 Dora Hughes, Health Affairs Blog, Minority Health Legislation In The 110
th Congress (March 14, 
2008), http://healthaffairs.org/blog/2008/03/14/minority-health-legislation-in-the-110th-Congress/. 
39 Id.   12 
communities.”
40  Since 2000, however, several health disparities bills have been introduced but 
have failed to pass both houses of Congress.
41  Currently, “[t]he prospects for a minority health 
and health disparities bill being signed into law in 2008 are uncertain. The opposition by some 
House Democrats as well as some Senate and House Republicans, the inevitable slowdown of 
congressional activity during election years, and the general difficulty of passing any bill are 
significant challenges to moving the bill.”
42  These political realities and other potential barriers 
will be discussed later in addressing the political feasibility of the FDA taking a more prominent 
role in the fight against health disparities. 
 
WHERE WE STAND NOW 
The recently-released 2007 AHRQ report on healthcare disparities shows little 
improvement since the initial findings were released, and in some instances the disparities have 
increased.
43  This regression has been observed by other organizations and agencies attempting 
to quantify progress as well
44 and indicates that it is time for government agencies to view the 
                                                 
40 Id. 
41 Id. (“In 2003 . . . Democrats in the Senate and the House introduced a democratic caucus minority 
health bill entitled the Healthcare Equality and Accountability Act (S 1833) . . . Sen. Bill Frist (R-TN) 
introduced Closing the Health Care Gap (S 2091) in early 2004, which, although more modest in scope, 
addressed many of the same concerns as the democratic caucus bill. Neither bill passed the Congress, and 
current efforts have focused on negotiation of bipartisan legislation.”) 
42 Id. 
43 Agency for Healthcare Research and Quality, National Healthcare Disparities Report  iv (2007), 
http://www.ahrq.gov/qual/nhdr07/Glance.htm  (last visited May 16, 2008). 
Overall, disparities in quality and access for minority groups and poor populations have not been reduced 
since the first NHDR. Based on 2000 and 2001 data compared with this year's 2004 and 2005 data 
(depending on the data source), the number of measures on which disparities have gotten significantly 
worse or have remained unchanged since the first NHDR is higher than the number of measures on which 
they have gotten significantly better for Blacks, Hispanics, American Indians and Alaska Natives, Asians, 
and poor populations. Id. 
44 The Office of Minority Health, A Strategic Framework for Improving Racial/Ethnic Minority Health 
and Eliminating Racial/Ethnic Health Disparities (20008), 
http://www.omhrc.gov/npa/templates/content.aspx?ID=78&lvl=1&lvlID=13 (last visited May 16, 2008) 
(“In many cases, the health gaps identified in the 1985 Task Force Report have grown.”).   13 
problem holistically and to implement creative policies that will improve the health of minority 
communities.  In April of 2008, the Office of Minority Health announced the release of a 
Strategic Framework for Improving Racial and Ethnic Minority Health and Eliminating Racial 
and Ethnic Health Disparities.
45  The report mentioned that “[t]he ultimate goal, for all 
stakeholders, is that individual and collective efforts on behalf of racial/ethnic minority health 
will be more evidence-based and will use available resources effectively and efficiently.”
46 
 
A STRATEGIC FRAMEWORK 
In April of 2008, DHHS’ Office of Minority Health released a Strategic Framework for 
Improving Racial/Ethnic Minority Health and Eliminating Racial/Ethnic Health Disparities.
47  
The document “reflects current knowledge and understanding of the nature and extent of health 
disparities, their causes or contributing factors, effective solutions and desired outcomes and 
impacts.”
48  The framework emphasizes what it calls a “systems approach” – an approach where 
“all parties engaged . . .are, themselves, part of a ‘system’ or ‘nested’ systems. As such, each 
party considers the causal or contributing factors and problems it is most likely to be able to 
impact with its particular strengths and talents.”
49  The components of the five-part strategy 
include: 
(1) examination of the long-term problems that OMH and others are trying to 
address, (2) review of the major factors known to contribute to or cause the long-
term  problems,  (3)  identification  of  promising,  best  and/or  evidence-based 
strategies and practices known to impact the causal or contributing factors, (4) 
presentation of measurable outcomes and impacts that might be expected from the 
                                                 
45 Id. 
46 Id. 
47 Id. 
48 Id. 
49 Id.   14 
strategies  and  practices  and  (5)  assessment  of  the  extent  to  which  long-term 
objectives and goals have been achieved.
50  
The framework can serve as a strategic planning guide for agencies to determine approaches and 
initiatives that may be successful in addressing disparities.
51  Specifically, application of this 
framework can help to define the role the FDA can and should play in the effort to eliminate 
racial and ethnic health disparities.  
 
III. THE ABSENT PLAYER – THE FDA 
Despite the broad range of federal initiatives outlined above, the Food and Drug 
Administration (FDA) has largely been absent from the department-wide initiatives to reduce 
and/or eliminate health disparities.
52  This absence is troubling, considering the breadth of the 
FDA’s regulatory authority and its control over several markets that directly affect the health of 
consumers:  “Products accounting for no less than 25 cents of every dollar spent by American 
consumers are under the jurisdiction of the FDA, approximately $1 trillion annually, including 
all foodstuffs excepting meat and poultry and all human and animal drugs and therapeutic 
devices.”
53  The breadth of this regulatory authority shows that the FDA is optimally placed to 
have a true impact in terms of implementing healthier changes in the way food products are 
made and distributed.
54  Yet, even legislators tend to overlook the broad reach of the FDA in 
drafting legislation to focus on health disparities.  The Minority Health and Health Disparity 
                                                 
50 Id. 
51 “The framework is intended to “help enhance the understanding of policymakers, policy analysts, 
researchers, practitioners and others about the key strategic components that must be addressed in 
developing policies or programs that affect racial and ethnic minority populations.” Id.  
52 See Lurie, supra note 28. (listing contributions of various government departments to leading health 
indicators. The FDA is not listed.). 
53 Ronald Hamowy, Government and Public Health in America 103 (2007).  
54 Id. ([The FDA] “ultimately has the power of life and death over hundreds of thousands of people 
suffering from fatal illnesses. We must all, at one point or another, rely on the FDA’s permission to obtain 
and ingest what might prove a life-saving medication prescribed by our physician without which we 
might well die.”]   15 
Elimination Act introduced in 2007 proposes to implement “an FDA advisory committee on 
pharmacogenomics and emerging issues,”
55 but fails to suggest any other creative solutions 
involving the FDA that could be reached through legislation relating to food safety, quality or 
nutrition.  With the FDA’s enormous authority should come the equally sizeable responsibility to 
act to protect and advance the public’s health with regard to health disparities.  The new Office 
of Minority Health Framework can provide guidance in assessing the FDA’s current and future 
role in this effort. 
 
APPLYING THE FRAMEWORK 
1)  Long-Term Problems 
2)  Contributing Factors 
3)  Support Effective Strategies and Practices  
4)  Measure Intermediate Outcomes and Long-Term Impacts 
5)  Achieve Long-Term Objectives and Goals 
Step one involves identifying the long-term problems.  This category also entails identifying 
the system-level “conceptual, organizational, structural and process-related variables that 
influence the ability to adequately and effectively address complex problems – and that can 
exacerbate these problems, or constitute problems in their own right.”
56  Regarding disparities in 
health status, the problem is clear: racial and ethnic minority groups experience poorer health 
than other population groups, and these disparities have persisted despite numerous public health 
interventions.  This first step also calls for an analysis of the “extent to which the systems (and 
the strategies/practices) are well-coordinated and strategically directed, and the extent to which 
                                                 
55 Barack Obama – U.S. Senator for Illinois, supra note 34. 
56 Office of Minority Health, supra note 44.   16 
existing stakeholder groups are willing to work together as parts of an interconnected system.”
57  
While the FDA does not currently play a major role in the effort to eliminate health disparities, 
other agencies have developed initiatives and have coordinated efforts in some cases. 
Step two divides the possible contributing factors in to three categories: individual factors, 
environmental or community factors, and systems factors.
58  Individual factors refer to the 
“knowledge, attitudes, skills, behaviors and biological or genetic risks” that impact health.  
Examples of environmental or community factors include “the physical environment (both 
natural and built), social and cultural characteristics of a community, and other economic, 
political and organizational/institutional conditions that are not generally within the control of 
specific individuals but provide the context of their lives.”
59  Finally, systems factors “include 
the kinds of systems that a community, state, region or nation might have (or not have), and 
approaches used (or not used), for identifying the problems or needs – health-related or 
otherwise – in their respective jurisdictions and for directing resources to address the problems or 
needs.”
60  As a federal agency, the FDA’s actions constitute systems-level factors that affect the 
problem.  However, the FDA has the ability, through regulation, to impact both individual and 
community level factors as well.  For example, the agency requires clinical studies that 
contribute to increasing the knowledge base and regulates the safety of the food supply in the 
community.  
                                                 
57 Id 
58 Id.   
59 Id. (“These factors may be either protective of, or pose risks to, health. Such factors include, but are not 
necessarily limited to: natural and physical hazards or biochemical risks, crime and violence, cultural 
values and norms that influence individual behavior and can protect or hinder the health and well-being 
of residents within communities, bias and discrimination, housing conditions and residential segregation, 
access to and quality of health care as well as schools, parks and recreational sites, nutritious food 
sources, transportation and other goods and services, communication networks and infrastructure, family 
and social networks or other supports for diverse segments of the community, low-income and poverty, 
unemployment, and the lack of health insurance.”) (emphasis added). 
60 Id.     17 
Step three involves incorporating effective strategies and practices to address the factors 
at every level outlined in step two.  Successful individual-level approaches “tend to reflect 
integrated approaches that address a combination of individual-level factors as well as their 
interactions with environmental factors that inhibit or support desired behaviors.”
61  Community-
level strategies include the “promotion of a healthy physical environment through the 
development of policies that promote public health and safety.”
62  The systems level strategies 
are especially important as they relate to the FDA’s role as an agency.  The framework 
recommends “[e]stablish[ing], increas[ing] and strengthen[ing] system components and 
resources, such as infrastructure, staffing and funding to ensure specific attention to racial/ethnic 
minority health and health disparities.”
63  Because of the tension between the government’s 
efforts to address public health concerns and the public’s desire to be free from government 
intervention, most public health initiatives to date have targeted personal responsibility and have 
touted measures that individuals can take on their own to improve their health.  However, 
initiatives targeting individuals may actually increase health disparities because disadvantaged 
groups may be in less of a position to make changes, while the status of advantaged groups will 
improve. 
“To the extent that health initiatives are not tied to individual action, all social groups are 
more likely to benefit in comparable ways. Thus, fluoridation of water supply, fortified 
foods, or environmental controls that reduce toxic pollution, such as the elimination of 
lead  from  gasoline  and  paints,  are  less  likely  to  result  in  disparities  than  initiatives 
encouraging voluntary efforts such as educational campaigns to promote careful tooth 
brushing, preventive fluoride treatment, increased exercise, or improved nutrition.
64 
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Thus,  the  FDA’s  strategic  approaches  should  consider  incorporating  community-level 
interventions that will provide benefits regardless of the capabilities of any one individual. 
Step four involves measuring intermediate outcomes and long-term impacts.  Once again, 
this step is subdivided along the three categories of contributing factors to health disparities.
65  
While the report lists a range of expected outcomes, relevant outcomes include:  
Decreased exposure to risks in the physical environment; Increased community assets 
that are protective of the health and well-being of its residents (e.g., health centers in 
underserved  communities,  neighborhood  restaurants a nd  grocers  with  healthy  food 
options, faith-based organizations, gathering place); Increased engagement in/adoption of 
healthy  lifestyle  and  appropriate  health-seeking  behaviors,  reduced  engagement 
in/adoption of risky behaviors; Increased inputs, assets and other resources allocated for 
racial/ethnic minority health and health disparities – in general and for specific priorities; 
and Increased dedicated assets and other resources for minority health/health disparities 
(including, but not limited to, state offices of minority health) and related priorities (as 
reflected in administrative, legislative, budgetary and other mandates).
66 
 
As the FDA mainly serves a protective role in ensuring the safety and efficacy of the foods and 
drugs that we ingest, its overall objective should be to decrease exposure to the risks that 
contribute to poor health outcomes.  In achieving this outcome, the FDA should work within its 
regulatory authority to ensure the availability of healthy food options and should dedicate 
resources to explore the role foods and drugs have played in creating and maintaining racial and 
ethnic health disparities. 
Finally, step five emphasizes establishing and measuring progress in achieving the long-term 
goals.  This final step is critical and involves the recognition that health disparities are a problem 
that was created over time and that will take time to eliminate.  Unfortunately, as noted by 
Nicole Lurie in discussing the role of the federal government in improving social determinants of 
health, “Our nation’s investment portfolio with regard to health is weighted far toward short-term 
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returns.”
67  As a public health agency, the FDA should commit itself to help minimizing the 
inequitable death and disability caused by preventable health hazards that can be found in food 
as well.
68 
 
IV. HISTORICAL APPROACHES AND MISSED OPPORTUNITIES 
Despite its failure to launch a comprehensive approach to eliminating health disparities, 
the FDA has not been entirely silent in the debate over the last twenty years.  Several regulatory 
decisions and high-profile litigation cases drew attention to the role that the foods we eat and the 
medications we take plays in health status, especially for minorities and socioeconomically 
disadvantaged populations.  However, some of these controversies also exposed the 
opportunities that the FDA has missed to both become a leader in the fight against health 
disparities and to develop viable strategies to eliminate the harms. 
 
THE BIDIL CONTROVERSY 
The FDA made a decision in 2005 that was heralded by some as a medical breakthrough 
and a welcome focus on disparities, and condemned by others as a step backward toward racist 
characterizations of genetic inferiority.  The agency approved a heart medication to be marketed 
exclusively to African American patients.  The drug, called BiDil, is not entirely original, but 
combines two generic medications “long recognized as benefiting patients with heart failure, 
irrespective of race or ethnicity.”
69  Medco, a pharmaceutical company based in North Carolina, 
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sought to obtain exclusive patent rights to the generic combination by submitting a new drug 
application (NDA).
70  The FDA originally rejected the NDA for BiDil because the 20-year old 
statistical data submitted in support of the application did not meet certain FDA statistical 
guidelines.
71  After the application was denied, researchers re-analyzed the data by race and 
found that the African American patients in the study were significantly more responsive to the 
therapy.
72  The researchers then obtained a new methods patent that specified the drug’s use “in 
an African American patient”
73 and licensed the drug to the biotechnology company NitroMed.
74  
In 2001, NitroMed announced that it had received a letter from the FDA “commenting on the 
ultimate approvability of BiDil as a race-specific drug, pending the successful completion of a 
confirmatory trial in African American subjects.”
75  The company then conducted the African 
American Heart Failure Trial (A-HeFT) to test the drug in heart failure patients who self-
identified as African American.
76  The results of the trial showed a significant increase in 
survival rates for those in the treatment group – so significant, in fact, that the trial was 
discontinued because continuing to deny treatment to the placebo group would have been 
considered unethical.
77  In the approval decision, the FDA “depart[ed] from its long history of 
approving drugs for general clinical indications without regard to demographic classification, . . . 
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[and] cited the need to address racial disparities in health as an important contributor to their 
decision.”
78   
To the extent that personal bias and prejudice may influence the behavior of physicians, 
initiatives that emphasize biological differences based on race may further disadvantage efforts 
to encourage physicians to regard patients equally.  The FDA’s decision has been called “a 
setback in the scientific and policy discourse on medical therapeutics and race [that] . . . 
specifically hinders the efforts aimed at eliminating health and health care disparities.”
79  One 
article summarized the concerning implications of BiDil’s approval as follows:  
(1) Drug approval for specific groups implies a differential drug response that has 
not been rigorously tested; (2) In approving a drug for a specific racial group, the 
FDA creates incentives for pursuing trials in less diverse patient populations; (3) 
In creating incentives for studies in less diverse patient populations, the FDA 
decision  may  lead  to  a  diversion  of  resources  away  from  studies  of  better 
therapeutics to those that support niche marketing; (4) By endorsing race as a 
treatment  indication,  the  FDA  unscientifically  endorsed  a  biological  model  of 
race; (5) The use of the health disparities argument to justify approval suggests a 
“solution”  (race-targeted  pharmacology)  for  a  “problem”  (racial  disparities  in 
health) and elevates biological difference in medication response to an important 
cause of health disparities without evidence; (6) The use of health disparities to 
justify the “creation” of an expensive medication is perverse.
80  
 
PROFIT MOTIVES 
Opponents of FDA’s actions argue that “[w]ithout playing the race card, NitroMed might 
never have raised the money needed to conduct A-HeFT.”
81  However, considering all sides of 
the debate, the statement is not necessarily a negative fact – had NitroMed not “played the race 
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card,” a drug that that has proven extremely efficacious in saving the lives of African American 
patients (and unknown numbers of other patients with heart failure), may have never been 
brought to market.  The reality of the American market is that medical interventions are rarely, if 
ever, pursued in the absence of significant financial incentive.  A NitroMed executive even 
acknowledged this financial incentive, arguing that “developing drugs for underserved 
populations . . . makes ‘good business sense,’ as these populations have been largely untapped by 
the pharmaceutical industry.”
82  However, NitroMed’s hiring of an advertising agency best 
known for its beer and car marketing to handle the marketing of the drug to African Americans is 
troubling and possibly shows how easily the promise of pharmacogenomics can devolve into 
racial stereotyping.
83  
Yet another concern is that this focus on genetics-based medicine could potentially lead 
to more health disparity in terms of treatments.  While the new frontier of pharmacogenomics 
has been touted for the potential to revolutionize medicine through personalized drugs, “little 
consideration has occurred regarding how pharmacogenomic medicine may affect the principle 
of distributive justice, and, in particular, who will benefit from newly developed tailored 
drugs.”
84  Minority groups could be at a disadvantage since engineering drugs for smaller 
populations would be viewed as less lucrative.
85 
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PHARMACOGENOMICS - PROBLEMS AND PROMISES 
Amidst the controversy, however, several prominent African American organizations 
have supported the development of BiDil.  The Association of Black Cardiologists (ABC) 
publicly expressed its support for the A-HeFT trial.
86  However, these groups reject the assertion 
that BiDil is a “race drug.”
87  Others have condemned the FDA for allowing NitroMed to take 
advantage of race as a marketing tool to gain increased profit on a drug that could benefit a wider 
audience,
88 and argue that the agency’s action “threatens to set in motion a trend in the 
pharmaceutical industry for turning other widely used and cost-effective generics into patented, 
expensive drugs in the name of alleviating health disparities.”
89  The makers of BiDil initially 
sought approval of the drug across all populations and only sought the race-specific patent when 
approval seemed otherwise unlikely – a move that suggests the company was only interested in 
the benefits it could bring to African Americans if there was a profit potential.
90  The new patent 
gives NitroMed exclusive marketing rights to market BiDil as a “method” to treat African 
American patients for heart failure until the year 2020.
91 
 According to Sandra Soo-Jin Lee of the Stanford Center for Biomedical Ethics, “[t]he 
use of race as a proxy for genetic relatedness has been widely criticized.  The conflation of race 
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with genetics opens the door to prejudice, racial stereotyping, and overly simplistic 
conceptualizations of pharmacogenomic interactions, which could ultimately lead to poor health 
care.”
92  Additionally, there is the concern that this approval paves the way for companies to 
avoid the costs of gene-specific pharmacogenomic testing by relying on self-identified race 
instead “as a proxy for genetic variation.”
93 
“The problem with BiDil is not only that it biologizes race but also that it uses 
race  as  biology  to  create  the  impression  that  the  best  way  to  address  health 
disparities is through commercial drug development. By exploiting race in the 
service of product promotion, it distorts public understanding of health disparities 
and of efforts to address them.”
94 
 
Despite the concerns, there are many promising aspects of pharmacogenomics that have 
the potential to revolutionize the way medicine is administered.  Researchers hope to be able to 
tailor medications more closely to an individual’s genome to reduce the risk of adverse drug 
reactions.
95  In addition, the ability to identify and target individuals with genotypes likely to 
respond to a particular medication could ultimately decrease the cost of clinical trials, since 
fewer individuals would need to be recruited to observe the drug’s efficacy.  However, while this 
would likely result in drugs receiving approval quicker and at a lower cost, they would be 
approved for these specific populations alone.
96  This limitation could be of particular concern, 
since “compelling evidence does exist to support the more reasonable claim that racial or 
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ethnocultural differences in pharmacodynamics may warrant the use of safeguards to protect 
minority access to needed medications.”
97  While pharmacogenomics brings the promise of 
personalized medicine, the FDA should consider implementing safeguards to ensure that 
minority populations will retain access to safe and effective medications even if their genotypes 
are not deemed profitable. 
The FDA should also implement better data collection and analysis protocols for the 
reporting of adverse events by race and ethnicity.
98  While differences in efficacy have been seen 
to vary by race/ethnicity, a systematic data collection system is needed.
99  “[S]cientists have 
copiously reported racial and ethnic healthcare disparities across an impressive array of disease, 
whereas simultaneously underreporting on therapeutic safety and efficacy for minority 
populations.”
100  Finally, the FDA should not ignore the potential for discrimination to cloud the 
promise of pharmacogenomics.  While some researchers argue that advances in genome mapping 
and genetic technologies will “render race, as defined by distinctive genetic signatures, obsolete . 
. .[u]nderlying this prediction of a race-free genomic era is the assumption that research on 
human genetic variation will proceed untainted by dominant social ideas and values regarding 
what constitutes human difference.”
101 
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OBESITY LITIGATION 
A string of recent lawsuits have targeted fast food companies, alleging a failure to warn 
their consumers of the potential harm of ingesting a steady diet of fast food products.  Modeled 
after the successful lawsuits against tobacco manufacturers, consumer groups have brought class 
action cases against several major fast food manufacturers.
102  The groups rely on the changes 
subsequently implemented by the tobacco industry “as supposed proof that litigation increases 
public knowledge, forces companies to stop objectionable marketing practices, and drives up 
prices for the targeted items, which in turn reduces consumer demand for allegedly unhealthy 
choices.”
103  The first of these cases to make it in to court was a 2003 case alleging that “foods 
from McDonald’s were dangerous beyond the extent ordinarily understood by consumers, that 
McDonald’s negligently failed to warn consumers of the risks, and that the company’s marketing 
constituted deceptive business practices under the state’s consumer-protection laws.”
104  The 
lawsuit was eventually settled,
105 but not before the U.S. House of Representatives introduced a 
bill in 2004, known as the “Cheeseburger Bill,” with the goal of preventing future such 
lawsuits.
106  The bill did not receive approval in the Senate, but it spurred several states to act on 
their own.  As of 2006, twenty-one states had passed laws exempting fast food chains from 
obesity lawsuits.
107  Another lawsuit filed in 2006 targeted Kentucky Fried Chicken’s use of 
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trans fats in its fried chicken.
108  The chain of fried chicken restaurants has since removed trans 
fats from most of its products.
109 
 
TOBACCO REGULATION 
Nearly every article on efforts to reduce or eliminate health disparities mentions tobacco control 
as an important objective.  FDA’s efforts to regulate tobacco product manufacturing and 
advertising are perhaps one of the agency’s most publicized public health initiatives.  In 1996, 
the FDA attempted to assert regulatory authority over cigarettes and smokeless tobacco as 
“delivery devices for nicotine, an addictive drug.”  The Federal Food Drug and Cosmetic Act 
(FDCA) defines “drugs” as “articles (other than food) intended to affect the structure or any 
function of the body.”
110  The agency drafted a regulatory rule that defined tobacco products as 
combination products – or products that are made up of both drugs and devices.
111  Since the 
FDA has discretion to choose whether to regulate such combination products as a drug, device, 
or biologic product,
112 the agency chose to regulate tobacco products as devices because the 
device regulatory provisions “offer the agency greater regulatory flexibility than do the drug 
provisions of the act.”
113 
In the 2000 case of FDA v. Brown & Williamson, the Supreme Court invalidated the 
FDA’s assertion of regulatory authority.
114  In its decision, the Court found that in passing the 
FDCA, Congress had not intended to afford the FDA regulatory authority over tobacco 
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products.
115  The Court reasoned that since the FDCA prohibits the marketing of any product that 
is not “safe and effective,” the FDA would be forced to ban cigarettes and smokeless tobacco, 
products that have proven to be unsafe – an action that “would plainly contradict congressional 
intent.”
116  The Court’s holding “made it clear the Congress would have to enact legislation 
giving FDA statutory authority over tobacco products in order for the agency to assert 
jurisdiction.”
117  Congress answered by drafting language providing the FDA with such authority 
in the 105
th and 107
th Congresses, but none of the bills were ultimately successful.
118 
In February of 2007, “lawmakers reintroduced bipartisan, bicameral legislation . . . to 
give the Food and Drug Administration (FDA) broad new authority to regulate the manufacture, 
distribution, advertising, promotion, sale, and use of cigarettes and smokeless tobacco products.”  
The bill, the Family Smoking Prevention and Tobacco Control Act proposes to “create a new 
Chapter IX in the Federal Food, Drug, and Cosmetic Act . . . solely for the regulation of tobacco 
products.”
119  The provisions of the bill would allow the FDA to: 
(1) restrict tobacco advertising and promotions, especially to children; (2) develop 
standards that require changes in tobacco product composition and design, such as 
the reduction or elimination of toxic chemicals; and (3) require manufacturers to 
obtain  agency  approval  in  order  to  make  reduced-risk  and  reduced-exposure 
claims for their products.
120  
 
Somewhat surprisingly, the largest cigarette manufacturing company, Philip Morris, supports the 
proposed bill.  The company had earlier announced its support for FDA regulation of cigarettes 
in a 2001 white paper.
121  The Philip Morris statement said: 
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FDA should require that ingredients added by the manufacturers do not increase 
the  inherent  risks  or  addictiveness  of  smoking  .  .  .  [and]  should  continue  to 
address  the  broad  issues  of  disclosure  (e.g.,  the  content  of  warning  labels, 
information about ingredients and smoke constituents) so that adults [sic] smokers 
remain informed about health risks.
122  
 
However, the white paper stressed the need for adult autonomy and argued that the FDA should 
be able to “discourage their consumption, but should not restrict an adult’s ability to make a 
decision about smoking.”  Additionally, Philip Morris felt that “[t]he agency should have the 
authority to impose mandatory design changes to cigarettes to help reduce harm, provided the 
changes do not significantly diminish adult smokers’ enjoyment of the product.”
123 
If the legislation passes, it would allow the FDA to “require tobacco companies to 
disclose the ingredients in their products, remove harmful ingredients and ‘stop misleading the 
public about the dangers of smoking.’”
124  Providing the FDA with the authority to regulate 
tobacco products is an important step in the effort to eliminate racial and ethnic health 
disparities.  The harmful effects of cigarette smoking, on minority communities in particular, 
have been well documented.  “[A]lthough whites are more likely than blacks to be smokers, 
blacks die at higher rates of smoking-related diseases.”
125  Additionally, “[a]ggressive 
promotional marketing of tobacco products, alcohol, and unhealthy foods exploits the 
vulnerability of individuals and populations and targets specific population subgroups, including 
young people, members of ethnic minorities, and low-income populations.”
126  According to 
former Surgeon General David Satcher, “The tobacco companies get away with these harmful 
practices because no government agency currently has any real authority over how tobacco 
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products are manufactured or marketed.”
127  The proposed law would “authorize the FDA to 
regulate the advertising and promotion of tobacco products in order to protect public health [and 
would] give FDA the authority to modify the composition of tobacco products in order to protect 
public health.”
128  These two provisions are particularly important in addressing smoking trends 
in minority communities.  Tobacco companies have historically targeted minority communities 
through focused cultural promotions.
129  There is also evidence that tobacco manufacturers hired 
professional basketball players to become spokesmen and sponsored jazz festivals to appeal to 
the African American community.
130  The preference among African American smokers for 
menthol cigarettes is likely a result of this targeted marketing.  Minority smokers tend to favor 
menthol flavored cigarettes, whose cooling effect may increase their exposure to nicotine and 
other harmful chemicals in cigarettes by allowing smokers to inhale more deeply.
131  “National 
Cancer Institute data shows that African-American men get lung cancer at a rate 50 percent 
higher than white men — a gap that most scientists say cannot be fully explained by historically 
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higher rates of smoking by black men.”
132  There is also evidence to suggest that menthol 
cigarettes are more addictive.
133  Unfortunately, the proposed bill exempts menthol from the list 
of “characterizing flavors” that would be prohibited.
134  However, the law would authorize FDA 
to “develop product standards to reduce nicotine, reduce or eliminate other harmful constituents, 
or otherwise modify the composition and testing of tobacco products, if it determined that such 
regulation was appropriate to protect the public health.”
135 
FDA would be required to make [a product standard] determination based on a 
consideration of the risks and benefits to the population as a whole, which is the 
approach favored by public health officials. Unlike some of the previous FDA 
tobacco bills, there is nothing in H.R. 1180/S. 625 to prevent the agency from 
requiring changes in the composition of tobacco products that would render them 
‘unacceptable for adult consumption.’ Placing that restriction on FDA’s ability to 
modify tobacco products had been a key requirement for the industry.
136  
 
Thus, it remains to be seen whether the industry will wholeheartedly support this legislation 
without such a restriction.  
 
TOXIC PLASTIC 
Within the last month, increasing attention has focused on the potential risk posed by the 
leeching of toxic chemicals from certain plastic containers.  The National Toxicology Program 
(NTP), housed within the U.S. National Institute of Environmental Science, released a report 
warning of the potential dangers of exposure to a chemical found in plastic bottles and canned 
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goods.
137  The chemical, Bisphenol-A (BPA) is used to make “epoxy resin and polycarbonate 
plastic products, including some kinds of water bottles, baby bottles, and food storage and 
heating containers. It is also used in the lining of metal food cans.”
138  According to the Centers 
for Disease Control and Prevention (CDC), “[m]ore than 90 percent of Americans are exposed to 
trace amounts of bisphenol. . . . The chemical leaches out of water bottles, the lining of cans and 
other items made with it.”
139  Exposure to the chemical is increased if the plastic is heated. 
The NTP study found that rats exposed to low doses of BPA developed precancerous 
tumors, urinary tract problems and experienced early onset of puberty.
140  The NTP report 
concluded that “there is some concern for neural and behavioral effects in fetuses, infants, and 
children at current human exposures.”
141  On the five-level scale of concern used by the NTP and 
the Center for the Evaluation of Risks to Human Reproduction (CERHR), some concern is the 
middle level.
142  However, despite this moderate level of concern, numerous studies have found 
disturbing effects from BPA exposure, such as “changes in tissue enzymes and hormone 
receptors as well as interacting with other hormone-response systems.”
143  Alarmingly, 
“numerous studies indicate a wide range of health effects from exposure to bisphenol-A at 
significantly lower doses (as low as 2 parts per billion in some studies) than considered ‘safe’ by 
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the EPA.”
144  One study found that “women with a history of recurrent miscarriage had average 
blood serum levels of bisphenol-A at 2.59ng/ml, more than three times higher than women with 
successful pregnancies.”
145  Researchers have also found evidence that exposure to the chemical 
can increase insulin resistance and may increase the risk for type II diabetes and hypertension.
146 
The implications of the findings for infants and young children are particularly troubling 
because they “are more likely to absorb more toxins . . . because they . . . eat and drink more in 
proportion to their body weight than do adults.”
147  While BPAs are a health concern for anyone 
exposed, poor people may be particularly disadvantaged because they may not be able to afford 
to follow the guidance that recommends reducing consumption of canned goods, which are 
typically one of the cheapest grocery options available.
148  Additionally, while several retailers 
have pulled bottles containing BPA and manufacturers have begun to implement changes,
149 
there currently is no alternative to the plastic liners in cans that contain BPA
150  Thus, absent 
government intervention, certain populations may not be able to decrease their exposure to this 
harmful chemical. 
While the National Toxicology Program report has raised awareness about this harm, the 
program has no regulatory authority to act on these concerns.
151  The publicity is raising worry 
that the current regulatory system for toxic chemicals is dangerously outdated.  Toxic chemicals 
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in food products are regulated under the Toxic Substances Control Act (TSCA), which 
reportedly has the distinct honor of being “the only major environmental or public health statute 
that has never been updated” since its enactment in 1976.
152  The Environmental Protection 
Agency (EPA), which administers the TSCA, “considers exposure to 50µg/kg/day of bisphenol-
A safe, [but] this standard was set in 1993 and is based on studies from the 1980s.”
153  While the 
EPA ultimately has regulatory authority over the approval of such substances for use in 
manufacturing plastics, the FDA is responsible for protecting against the introduction of such 
chemicals into the food supply.  However, “[t]o date, the U.S. Food and Drug Administration has 
not performed a standard toxicology study or determined an Acceptable Daily Intake (ADI) for 
bisphenol-A.”
154  The regulation of chemicals that are involved in food storage is an area in 
which the EPA and FDA should especially collaborate effectively to ensure the health of the 
public.   
  In response to the report, a number of state governments and foreign countries have 
already taken action to restrict or ban the use of BPA.  Canada immediately proposed a ban on 
the chemical in baby bottles.  In announcing the ban, Tony Clement, the Canadian health 
minister stated, “We have concluded that it is better to be safe than sorry.”
155  So far, the U.S. 
government response has been minimal.
156  The FDA has formed a BPA task force “to facilitate 
cross-agency review of current research and new information on BPA for all FDA regulated 
products.”  The charge of the group is to “make recommendations to the Commissioner 
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regarding next steps.”
157  In the meantime, the FDA has issued the following statement on its 
website: 
At this time, FDA is not recommending that anyone discontinue using products 
that  contain  BPA  while  we  continue  our  risk  assessment  process.  However, 
concerned consumers should know that several alternatives to polycarbonate baby 
bottles exist, including glass baby bottles.
158 
 
V. OPPORTUNITIES FOR ACTION 
While the FDA has taken some actions that contribute to efforts aimed at eliminating 
racial and ethnic health disparities, such actions have not necessarily been framed as part of a 
coordinated effort to address these inequities.  In addition to framing strategies around the issues 
outlined above, the following suggestions outline areas in which the FDA can further commit to 
fighting health disparities. 
 
OFFICE OF MINORITY HEALTH IN FDA 
Congress passed legislation in 1994 that created the Office of Women’s Health within the 
FDA.
159  However, legislation that would create a similar focus on minority health within the 
FDA has stalled.
160  Since 1994, the increased focus on women’s health has also brought 
attention to racial and ethnic groups as another minority population with specific health-related 
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concerns.  The Food and Drug Administration Modernization Act (FDAMA) of 1997 directed 
the development of “guidance, as appropriate, on the inclusion of women and minorities in 
clinical trials.”
161   
Accordingly, the Center for Drug Evaluation and Research (CDER) within the FDA 
commissioned an ad hoc working group to study and implement the 1997 directive.
162  The 
group “recommend[ed] that the Centers consider instituting a permanent tracking system to 
monitor effectiveness and safety data for gender and racial subgroups submitted under the new 
final rule,”
163 and delegated the task of designing such a system to the “FDA Office of Women’s 
Health, Gender Effects Steering Committee, CDER senior management team, and CDER’s 
Women’s Health Subcommittee of the Medical Policy Coordination Committee.”
164  It is 
curious, however, that the tracking of racial and ethnic minority data was undertaken by a 
steering committee focused on women’s issues.  The inclusion of racial subgroups seemed to be 
an afterthought.  The FDA should consider either forming an entirely separate Office of Minority 
Health or expanding the existing Office of Women’s Health to show a true commitment to 
eliminating disparities.  The Working Group even seems to acknowledge its limitation:  
The portion of the 1993 Gender Guideline cited above clearly articulates the 
expectation of FDA that all appropriate demographic subgroups should be 
included in product development, but the fact that this statement is found in the 
Gender Guideline conceivably might diminish its impact on minority 
recruitment.
165 
 
However, in explaining the focus on women as opposed to minorities, the committee reports that 
“[u]nlike women with childbearing potential, there has never been a regulatory barrier to the 
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inclusion of minorities in clinical trials and there does not exist a guidance that addresses only 
the issue of minority enrollment in clinical trials.”
166  This statement demonstrates that the 
Working Group either does not recognize or has chosen to ignore the history of racism and 
exclusion in the relationship between minorities and the health care system.  It is also notable 
that of the fourteen representatives of the FDAMA Women & Minorities Working Group listed 
in the report, not one appears to have a background or specialty focus in health disparities or 
minority health, despite the existence of the HHS Office of Minority Health at the time, which 
could have supplied a representative.
167  In a similar oversight, a representative from NIH’s 
Office of Research on Women’s Health was included, but there was no corresponding 
representative from the NIH’s Office of Research on Minority Health, which had been in 
existence since 1990.
168  
Due in part to the efforts of the OWH, the FDA in 1998 “required that anyone enrolled in 
clinical studies be identified by gender, age, and race and that safety and effectiveness data be 
evaluated to identify differences based on these same categories.”
169  Thus, while the existence 
of the OWH has benefited minority health by mandating greater collection of data on race in 
clinical studies, the persistence of racial disparities shows that a more focused approach is 
needed.  Addressing the role of race in health can no longer be considered an ancillary issue.  
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EXPANDING THE CONCEPT OF “FOOD SAFETY” 
TO COMBAT DIET-RELATED DISEASES 
 
The Obesity Epidemic 
The increasing rate of obesity in the American population has grown into one of the most 
pressing health concerns, across all subpopulations.  As depicted in books such as Fast Food 
Nation and in movies such as Supersize Me, Americans’ reliance on convenience food has led to 
an ever-expanding national average waistline.
170  Some attribute the phenomenon to increased 
food intake overall.  As food production has become cheaper over time, pre-packaged foods with 
high sugar or fat contents (also known as energy-dense foods) have become particularly 
convenient.
171  It is “against this backdrop of Americans’ sedentary lifestyles” that public health 
messages have targeted individuals, encouraging healthy food choices and daily exercise.  
However, the data shows that “most Americans are aware of these recommendations but fail to 
adhere to them.”
172  As a result, it is becoming apparent that solely focusing on individual 
behavior as a public health intervention, while necessary, will not be sufficient to stop the 
growing epidemic.
173 
The increased weight is taking a toll on consumer health.  Excess weight increases the 
risk for several serious medical conditions, including cardiovascular disease, stroke, and 
diabetes.  As noted by Madelon Finkel, professor of clinical public health at the Weill Medical 
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College of Cornell University, this disease pathway is particularly apparent in minority 
communities: 
The parallel obesity and diabetes epidemics reveal stark realities about the line 
between health and illness, a line that is influenced by genetics, race and ethnicity, 
and economics. The environment, too, influences the eating behavior of children 
and adolescents, as those who live in neighborhoods described as low income 
with high levels of poverty, low education, and low housing value are more likely 
to have poor dietary habits compared with those living in higher socioeconomic 
neighborhoods. On a national level, the risk of diabetes is at least twice as great in 
Mexican Americans, Puerto Rican Americans, and non-Hispanic blacks than in 
non-Hispanic  whites,  and  the  prevalence  of  physician-diagnosed  diabetes 
continues  to  rise  most  steeply  among  Mexican  Americans  and  African 
Americans.
174  
 
Indeed the prognosis for minority communities has been getting worse over time.
175  Increased 
morbidity from diseases such as diabetes and heart disease due to obesity has been a significant 
health burden for many minority groups.
176  This is particularly troubling with respect to efforts 
to eliminate health disparities because there are complicating factors that make reversal of the 
trend more difficult than simply advising people to eat a healthier diet.  While personal behavior 
and food choices are a factor, research has shown that the over-consumption of fast food and 
processed food by certain populations cannot be attributed to voluntary choice entirely. 
Researchers have found that “even in geographically close neighborhoods, race predicts the 
availability of healthy foods. Communities with higher home values and that are homogenous 
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have more supermarkets,”
177 and minority communities have been shown to have “higher 
concentrations of liquor stores, bars, fast food restaurants, and advertisements for tobacco and 
alcohol.”
178  Other studies have found that produce is 22% more expensive in poorer areas, and a 
typical market basket for four would cost the family 15% more in a less affluent area.
179  
Numerous studies have documented these barriers to obtaining nutritious food in poorer 
communities and show that the burden of poor food quality is not evenly distributed.
180  Since 
low-income neighborhoods tend to be disproportionately populated with racial and ethnic 
minorities, these populations “have a significant disadvantage when it comes to the availability 
of healthy foods.”
181  Some critics argue that the disproportionate rates of obesity are simply due 
to a preference for unhealthy foods; however, studies suggest that the disparity is not due to a 
lack of awareness of what foods are considered healthy.  Researchers with the Continuing 
Survey of Food Consumption found evidence suggesting that “poor households do as well as 
non-poor households in knowing what they should purchase. They simply do not have the money 
to do it.”
182  Furthermore, economic analysis shows that consumers will buy the amount of food 
they can afford that “maximizes benefits such as taste and health and minimizes costs such as 
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financial burden or losing health.”
183  Thus, cash-strapped families will tend to choose cheaper, 
but more filling calorie-dense foods to stretch their budgets and stave off hunger.
184 
 
Past Strategies 
While the previous public health initiatives advising consumers to take notice of the 
quantity of their consumption and to be aware of the skewed perception of portion size
185 should 
continue, it is time to more closely scrutinize the components of the processed convenience 
foods that Americans are ingesting in ever-increasing quantities.  According to at least one 
report, “the single most important strategy [in reducing health disparities] would be to prevent 
and reverse obesity in poor and marginalized populations.”
186  To this end, the FDA should 
approach obesity with the same urgency as it would any other epidemic.  Historical approaches 
to other public health epidemics have included “targeted regulations, taxes, and policies at either 
the community or individual level to limit population exposure to substances or behaviors known 
to promote the epidemic.”
187  Efforts to reduce the alarming obesity epidemic should be no 
different.  The abundant data showing that the poor nutrition of disadvantaged populations is not 
merely a choice proves that the quality of fast food and convenience food is a public health 
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concern that needs to be addressed through the regulatory authority of the FDA by implementing 
changes that will have a beneficial effect.
188 
The FDA has taken steps in recent years to increase public awareness of the nutrition 
content of foods; however, “[g]iven the current obesity epidemic, the question is whether 
additional government interventions are warranted.”
189  Current proposals include “nutrition 
guidelines for foods sold anywhere in schools; mandated nutrition labeling in restaurants and 
‘food-away-from-home sources’; targeted taxes and subsidies; and a redesign of the federal Food 
Stamp Program.”
190  The labeling standards promulgated in 1990 provided consumers with 
detailed ingredient information on packaged foods, but exempted restaurants.
191  More recently, 
the FDA issued a final rule in 2003 requiring manufacturers to list the amount of trans fats in 
their products.
192  While these labeling provisions were necessary, they will not address the root 
cause of the disparity – access to and affordability of healthy food.  Thus, minority populations 
remain disproportionately impacted and unprotected from the harmful contents of fast food 
because they do not always have the choice to consume in moderation.  Under the Food Drug 
and Cosmetic Act (FDCA), the FDA has the authority to establish “reasonable standard[s] of 
quality” for foods.
193  The FDA should consider utilizing this authority to mandate better quality 
of all foods, particularly with regard to ingredients known to be harmful to health, such as trans 
fats and excess amounts of sodium.
194 
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The Trans Fat Debate 
Trans fats are a type of unsaturated fat that is created by adding hydrogen to oil, such as 
vegetable cooking oil.  The process of partially hydrogenating cooking oils is used to increase 
the shelf life by eliminating the linolenic acid in the oil that would otherwise turn the oil rancid 
over time.
195  The byproduct of this process results in trans fats in foods cooked with 
hydrogenated oils – which is associated with an increased risk of cardiovascular disease.
196  
Trans fats have been referred to as “absolutely the worst type of fat,” and consumers have been 
advised to eliminate products containing trans fats from their diets altogether.
197  The FDA 
issued a rule in 2003 requiring that all food manufacturers list the trans fat content of their 
products on the food label within the next three years.
198  While this action fell short of a ban, the 
“sunshine effect” of being forced to disclose trans fat content may pressure the corporations to 
develop trans-fat free alternative products.
199  Indeed, there is some evidence that this pressure is 
leading companies to stop using partially hydrogenated oils.
200  However, the FDA should not 
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shy away from adopting a more direct approach to mandate removal of certain harmful 
ingredients. 
Given the numerous studies showing the increased health risks associated with 
consumption of trans fats, the FDA should consider banning all foods containing trans fats as 
“adulterated” food products.  The FDCA considers food adulterated if it “bears or contains any 
poisonous or deleterious substance which may render it injurious to health.”
201  However, if the 
substances is not an “added substance” it is not deemed adulterated “if the quantity of such 
substance in such food does not ordinarily render it injurious to health.”
202  Food can also be 
considered adulterated if it contains “any added poisonous or added deleterious substance” that is 
considered unsafe under section 406.
203  Section 406 further deems unsafe “[a]ny poisonous or 
deleterious substance added to any food, except where such substance is required in the 
production thereof or cannot be avoided by good manufacturing practice.”
204  Within this 
regulatory framework, it is not clear whether trans fats would be considered an “added 
substance” or not.  However, there is a plausible argument that the current levels of trans fats in 
fast foods are injurious to the health of those who consume such foods at the average rate of most 
Americans.  The harm that a diet high in trans fats poses to cardiovascular health is well 
documented, and the FDA recommends avoiding it altogether, so it is arguably “injurious to 
health” in any quantity.  Most importantly, trans fats can be avoided in the manufacturing 
process.  The FDA can and should require food manufacturers to use alternative, safer 
ingredients.  
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An alternative approach would be to argue for restrictions on the quantity of trans fats 
allowed in a given food product.  The FDCA allows the FDA to promulgate regulations limiting 
the quantity of such unsafe substances “when such substance is so required or cannot be so 
avoided,” as long as the action is “necessary for the protection of public health.”
205  If the FDA 
relies on this provision to regulate the amount of trans fat in a given food product, the agency can 
avoid having to implement an overall ban on foods containing trans fats.  
 Much of the pushback from the industry argues that there are no alternative oils that 
would allow the foods to retain their signature taste.
206  McDonald’s has yet to remove trans fats 
from the oil used to prepare its french fries, citing the difficulty in duplicating the taste with 
alternative oils.
207  Other chain restaurants have reduced or eliminated the use of cooking oils 
containing trans fats, but have acknowledged that such efforts are complicated to implement 
while retaining the signature tastes of their foods.
208 
  If the FDA takes steps to ban trans fats, it will not be the first time the agency has 
considered or actually mandated major changes to food contents in response to public health 
concerns.  Past examples include efforts to encourage the fortification of foods, the regulation of 
margarine, and attempts to regulate MSG.  The fortification of foods came about due to concerns 
that individuals were not receiving adequate nutrition from the food supply because modern food 
processing methods often resulted in lower nutrient content.
209  Some states even mandated 
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fortification of foods.
210  Proactive measures should be considered again to avoid the harm of 
trans fats.  Instead of regulating to encourage the addition of a substance, the FDA could regulate 
to encourage or mandate its removal.  Such interventions are not without precedent.  In 2006, the 
city of New York banned trans fats in all restaurants.
211  Additionally, other countries have taken 
steps to restrict the levels of trans fats in foods without entirely banning them.  The country of 
Denmark has placed a ban on any food with a trans fat content that exceeds 2% of the total fat.
212  
Contrary to many of the industry objections to trans fat regulation, the restrictions in Denmark 
“had no noticeable effect on the availability, price, or quality of food items previously containing 
high amounts” of trans fats.
213  The FDA’s historical treatment of Margarine and Monosodium 
Glutamate in foods are also relevant.  Both were food ingredients once considered harmful 
enough to warrant significant restrictions.
214 
 
Sodium 
In addition to the concerns over trans fats, the FDA should also explore ways to limit the 
sodium content of foods. “It has been known for decades that sodium consumption can lead to 
salt-induced high blood pressure and is a significant contributor to heart disease and stroke.”
215 
Now, advocacy groups are recognizing this link and are calling on the FDA to act to protect 
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consumers, arguing that by reducing the amount of sodium in food by half, an estimated 150,000 
people’s lives could be saved each year.
216  The American Medical Association has called on the 
FDA to regulate salt as a food additive.
217  The move would require “[p]ackaged food companies 
. . . to adhere to limits on allowable sodium levels for various categories of foods.”
218  The FDA 
has yet to act on this proposal.  
 
Alternative Strategies 
FDA interventions combating diet-related diseases have primarily focused on requiring 
clearer labeling.  However, “[p]ast research suggests that the health benefits of additional 
nutritional information are modest at best.”
219  The time has come for the FDA to take a more 
aggressive approach to combat the obesity epidemic that is literally killing thousands of 
Americans.  There are other options the FDA could pursue if it declines to ban trans fats or if 
such efforts prove to be politically unfeasible.  These strategies include tougher labeling 
requirements, taxing “junk foods” more heavily, and mandating that healthier foods be served in 
schools and through other government-sponsored food programs.
220  Developing more creative 
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approaches to address public health concerns such as obesity and other diet-related illnesses is 
within the FDA’s authority to regulate in the interest of public health.
221   
 
Tougher Labeling 
Currently, the FDA exempts restaurants from the labeling requirement that applies to 
packaged foods.
222  The justification for the exception is the “belief that it is too difficult, given 
variations in how restaurant food is prepared, to provide accurate information on caloric or 
nutritional content.”
223  The FDA responded to calls to more strictly impose the current labeling 
requirements by issuing proposed rules in 2005 regarding caloric content and serving size 
labeling.
224  The demise of the nightly family sit-down dinner is one reason cited for the need for 
more stringent regulations of restaurant and fast food: 
The increase in consumption of food away from home (FAFH) has been one of 
the most notable changes in U.S. food consumption patterns over the last several 
decades.  .  .  .  Because  FAFH  foods  tend  to  be  of  lower  nutritional  quality 
compared  with  foods  prepared  at  home,  many  public  health  advocates  are 
implicating Americans’ increased reliance on FAFH as a contributing factor to the 
obesity epidemic.
225 
 
While some restaurant chains have taken the initiative on their own, some states have 
considered legislation to require the posting of nutrition information in fast food and chain 
restaurants.
226  Many argue that given the prevalence of family meals that are eaten outside of the 
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home and the related public health concerns, restaurants should no longer be exempt from the 
nutrition labeling requirement.
227  While opinion polls show that Americans are generally in 
favor of nutrition labeling requirements,
228 there is some evidence to suggest that even given this 
information, consumers will not change their energy intake habits.
229  Consumer education 
would likely also need to be a component of these labeling initiatives if they are to have any 
impact.
230 
 
Junk Food Tax 
Yet another proposal to address the obesity epidemic involves increasing the tax on “junk 
foods” such as “[f]ast food, carbonated beverages, and foods high in sugar and fat.”
231  Similar 
“sin taxes” have been leveled against tobacco products to encourage individuals to quit smoking.  
However, such proposals are ill-advised in the effort to eliminate health disparities, since they 
overlook the disproportionate impact such taxes would have on minorities, who would largely 
bear the financial burden when attempting to purchase lower-cost foods.
232  Furthermore, such 
taxes have not necessarily been shown to effectively reduce consumption,
233 and  polls indicate 
that such proposals to tax certain unhealthy foods would be unpopular.
234  
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Government Food Programs and School Food Initiatives 
Finally, government-sponsored food programs have been identified as another food 
source where quality regulation could impact public health.  “Citing a higher obesity prevalence 
rate among low-income groups, some have suggested that the FSP [Food Stamps Program] may 
be a contributing factor by promoting excess food consumption.”
235  However, the precise 
direction of causality should be more fully explored.  It is not clear whether lower income 
individuals are consuming more foods or are simply consuming foods with higher energy density 
(i.e. higher calorie foods with more fat/sugar content).  One suggested proposal is to limit Food 
Stamps-eligible foods to healthy options such as fruit and vegetables.
236  
School lunches and other foods available on school grounds have also raised concern.  
School lunches must adhere to minimal nutritional values, but the U.S. Department of 
Agriculture’s (USDA’s) standard “focuses on whether a food has at least minimal amounts of 
one of eight nutrients . . . [and] does not address calories, saturated or trans fat, salt, or added 
sugars.”
237  Currently, in the absence of such standards, “dietary fat in government-approved 
school lunches, for example, far exceeds recommended guidelines.”
238  Advocacy groups have 
also proposed regulations restricting the food available in school vending machines, citing the 
link between obesity and the sugar and high fructose corn syrup in sodas and candies.
239  Several 
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school districts have taken action already.
240  Because efforts to regulate the health and safety of 
children are often more politically feasible, “school-based interventions may be good candidates 
for public health nutrition interventions designed to curb the obesity epidemic.”
241 
 
Food Safety Regulation Generally 
Generally, in regard to drugs and food additives, there are a few simple ground 
rules on which we can probably agree. One is that large benefits certainly justify 
larger risks than small benefits, and that where there is no benefit, no risk is 
acceptable if it can be avoided. . . . It is more difficult to document that this has 
indeed  been  the  pattern  of  decision  making  for  compounds  at  the  margin  of 
decision making.
242 
 
Given the hesitation of the FDA to intervene aggressively to combat obesity through 
regulation, it is likely that trans fats and sodium are food additives at the margin where the 
balance between risks and benefits does not clearly weigh one way or another.  However, in 
framing the discussion as one of health inequities, “we must acknowledge the difference between 
publicly inflicted and privately accepted risks, namely those risks which one undertakes 
voluntarily and those which cannot be avoided because the rest of society imposes them upon 
us.”  It is not entirely clear into which camp the risk of a high trans fat diet falls.  Whether the 
significantly greater consumption of fast and processed food in minority communities is 
considered entirely voluntary, or is deemed unavoidable due to confounding social factors, will 
likely determine how aggressive an approach will be taken.  
 
 
                                                 
240 See Finkelstein, French, Varyiam, et al., supra note 171; see also Finkel, supra note 174 at 169 
(discussing school lunches) (“USDA’s standards apply only to food sold in the cafeteria, yet today 
vending machines in schools have proliferated.”). 
241 Finkelstein, French, Variyam, et al., supra note 171. 
242 Philip Handler, Introduction, in HOW SAFE IS SAFE? THE DESIGN OF POLICY ON DRUGS AND FOOD 
ADDITIVES 4 (1974).   52 
VII.  MEASURING PROGRESS 
As outlined in the final step of the OMH Framework, any strategic plan to eliminate 
racial and ethnic health disparities should also outline goals and define ways to measure 
progress.  An initiative called the DRA Project has also outlined criteria for “identifying the most 
important disparity reducing advances.”
243  The six main criteria advocate programs that: 
1.  Can make a very large, measurable difference in reducing health disparities 
2.  [Are] [c]ost-effective enough to be applied and reapplied, or be sustainable, as 
necessary 
3.  [Are] [a]ppropriate for multiple poor and marginalized populations 
4.  Encourage[] participation of individuals and key stakeholders 
5.  Can be communicated to decision-makers and the public 
6.  Can be realistically applied within the next 10 years.
244 
 
Additionally, quantitative models have been developed for measuring decreases in health 
disparity attributed to programmatic interventions;
245 however, “[w]hile a number of evaluations 
of health disparity reducing measures have been conducted, there are no conclusive answers to 
the question of what approaches are likely to have the most sizeable impact. There are no clear 
and undisputed winners.”
246 
 
VI. FEASIBILITY AND WEATHERING THE POLITICAL CLIMATE 
 
“Pretending that politics and science do not coexist is foolish, and cleanly separating 
  science from politics is probably neither feasible nor recommended.”
247 
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While brainstorming ways in which the FDA can play a larger role in the fight against 
health disparities is a necessary process, policymakers must also think realistically about what 
policies will be feasible to implement successfully, given the political climate.  As with any 
intervention, ideally, there should exist evidence-based research results on which to base 
conclusions before the program is initiated.  Unfortunately, “[t]he state of knowledge is not 
adequate at this time to have evidence based answers.”
248  While legislation has mandated the 
collection of data on the medical causes of health care disparities, “[l]ittle is known about the 
mechanisms through which nonmedical determinants, particularly those related to 
socioeconomic status and social conditions, affect health.”
249  However, many of the areas that 
the FDA could impact have reached the level of crisis.  Levels of obesity in the population, 
particularly among minorities, have been termed “epidemic.”  Thus, the FDA should act with the 
same speed with which it would address any other epidemic to implement effective policies to 
combat this trend. 
Complicating such efforts, however is the “divided public opinion about the role of 
government overall, as well as the role (if any) that government should play in health.”
250  As 
evidenced by the difficulty in getting legislation addressing minority health issues passed, policy 
priorities have not favored legislative interventions for this problem in the past.  Currently the 
federal response to these efforts is fragmented, and “[b]oth of the influential IOM reports 
indicate that the public health system – from the perspective of conventional standards and 
technical capacity – is in disarray.”
251  The report highlights the limitations of local health 
departments, a particularly troubling dilemma since local health departments are the most direct 
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conduit of public health messages and regulations to communities.  Even regulations 
promulgated at the federal level are typically carried out and supervised by these local agencies. 
However, several recent events may indicate a public readiness for change.   
John Kingdon described the combination of social and political circumstances that must 
be present for policies to successfully be developed and implemented as a “policy window.”
252  
The recent media attention around the possible toxicity of plastic containers may have opened a 
window of opportunity for action focusing on the long-term effects of food and processing on 
health.  Additionally, “[t]he results of recent opinion polls indicate that a majority of Americans 
believe that the government should be involved in fighting obesity.”
253  The FDA must capitalize 
on this public sentiment to gain support for initiatives to address the factors that impact racial 
and ethnic minority groups disproportionately.  Most importantly, the collective will for 
legislative action may be building.
254  While the strategies outlined above represent possible 
regulatory steps that the FDA can take on its own to direct a greater focus of its efforts on 
eliminating racial and ethnic health disparities, the agency should take advantage of 
opportunities to help shape potential legislative approaches should the policy window open. 
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